Pharmaceutical supply in Austria – Strategies for future security
Strategies for the future
Pharmaceutical product supply in Austria has become a central issue in politics, healthcare, and society. The media regularly report on shortages of important medicines – ranging from antibiotics to paediatric medicines. According to official data, more than 580 pharmaceutical products in Austria were unavailable or only available to a limited extent at the end of 2023. For patients, this means uncertainty; for the healthcare system, it means an enormous burden.
This development shows that Austria needs new strategies to ensure the long-term supply of pharmaceutical products. Strengthening regional production capacities, cooperating with strong industry partners and making investments in innovative technologies are key steps in order to reduce dependency on international supply chains and to enhance supply sovereignty within Europe.
The pharmaceutical industry is a major economic factor in Austria and forms the backbone of a high-performing healthcare system.
As a specialist in the manufacture and wholesale of pharmaceutical products, the industry ensures that the population’s supply security is maintained at all times. In Austria, numerous companies are active along the entire value chain – from innovative pharmaceutical companies and pharmacies to specialised providers of healthcare products. The procurement and manufacture of pharmaceutical products require close coordination among all parties, from the selection of high-quality raw materials and precise production to modern packaging and reliable delivery to pharmacies. In this way, the pharmaceutical industry contributes significantly to ensuring that patients have access to safe and effective pharmaceutical products.
Challenges in the supply of pharmaceutical products
The supply of pharmaceutical products in Austria is facing numerous challenges which affect the entire industry. One of the key tasks is ensuring supply sovereignty, particularly considering the steadily increasing demand of pharmaceutical products. At the same time, the highest standards of quality and safety must be met – both in manufacturing and in wholesale and distribution to patients. The pharmaceutical industry is confronted with the challenge of global supply chains, which are constantly tested by global developments and geopolitical tensions. In addition, strict EU regulations and national laws set high standards for efficiency and product safety. The growing importance of generics and biosimilars, along with ongoing digitalisation, requires the industry to develop innovative solutions and continuously adapt to new demands.
Pharmaceutical industry and the economy
The pharmaceutical industry is a central pillar of the Austrian economy and contributes significantly to GDP. With tens of thousands of jobs across Austria, the industry is not only a major employer but also a driver of innovation and growth. Substantial investments in the research and development of new pharmaceutical products and therapies strengthen competitiveness and create sustainable value. Close cooperation between pharmaceutical companies and research institutions supports the development of innovative products and secures Austria’s position as an attractive location for pharmaceutical research. In this way, the industry makes an important contribution to economic stability and the provision of healthcare for the population.
Pharmaceutical companies and their role
Pharmaceutical companies play a key role in the supply of pharmaceutical products. They are responsible for manufacturing, wholesale and the safe distribution of pharmaceutical products to pharmacies and healthcare facilities. In order to ensure supply sovereignty, they need to adapt to rising demand and evolving market conditions. Compliance with strict EU regulations and national laws is just as essential as maintaining the highest standards of quality and efficiency across all processes. Close collaboration with wholesalers and pharmacies enables the industry to meet patients’ needs effectively and to keep supply chains stable, even in challenging times. In this way, pharmaceutical companies make a significant contribution to ensuring that the supply of pharmaceutical products in Austria remains reliable and future-proof.
Internationale Zusammenarbeit
Die internationale Zusammenarbeit ist für die Pharmaindustrie von zentraler Bedeutung, da die Branche in einem globalen Umfeld agiert und von weltweiten Entwicklungen beeinflusst wird. Die Einhaltung von EU-Richtlinien und internationalen Standards für die Herstellung, den Großhandel und die Abgabe von Arzneimitteln ist dabei ebenso wichtig wie die Anpassung an die Vorgaben der Weltgesundheitsorganisation (WHO) und anderer internationaler Organisationen. Durch die enge Kooperation zwischen Pharmaunternehmen und Regulierungsbehörden wird sichergestellt, dass die Qualität und Sicherheit von Arzneimitteln auf höchstem Niveau bleiben. Diese partnerschaftliche Zusammenarbeit ermöglicht es, innovative Lösungen zu entwickeln, globale Herausforderungen zu meistern und die Versorgung der Patientinnen und Patienten in Österreich und darüber hinaus nachhaltig zu sichern.
International cooperation
Why do these shortages occur? The causes are diverse:
- Dependence on a limited number of production sites A large proportion of active pharmaceutical ingredients (APIs) is manufactured in Asia. If production disruptions or export restrictions occur there, European countries such as Austria are immediately affected.
- Just-in-time supply chains Over the years, manufacturers and wholesalers have minimised their inventory levels to reduce costs. This makes the supply chain more vulnerable to fluctuations in demand.
- Global crises & geopolitical factors The pandemic, trade conflicts or geopolitical tensions have clearly exposed the vulnerabilities of existing supply chains
- Lack of diversification Too few sites in Europe are specialised in the production of essential, frequently used pharmaceutical products.
In the context of global challenges such as COVID-19, changing trade policies and geopolitical uncertainties, it becomes clear how strongly these factors affect the stability and transparency of supply chains. These points highlight that the long-term supply of pharmaceutical products in Austria can only be secured through investment in European production capacities and flexible structures.
Austria’s approach: Resilience instead of risk
In recent years, Austria has begun to place the issue of pharmaceutical product supply more prominently on the political agenda. The aim is to reduce dependencies and strengthen supply sovereignty within Europe.
This involves several measures:
- Support for regional production: One example is the support of the penicillin factory in Tyrol to ensure the long term manufacturing of essential antibiotics in Europe. The diversification of production sites and their distribution across multiple countries increases the resilience of supply chains to global disruptions.
- Cooperation between policymakers, authorities and industry: Only through joint strategies can supply chains be stabilised and shortages be avoided.
- Investments in infrastructure and digitalisation: Modern production and packaging facilities not only increase flexibility but also enhance transparency for authorities and partners.
Complex Pharmaceuticals as a strategic partner
A key element of this strategy is collaboration with innovative companies that are building regional capacities. Complex Pharmaceuticals plays a distinctive role in this process:
- With a 7,800m² high-end packaging facility near Vienna, the company is strengthening Austria’s position as a pharmaceutical hub.
- GMP-compliant processes enable the safe and flexible handling of 1 to 1,000,000 packs – from micro batches to large-scale production.
- Modern production lines enable rapid format changes, which is particularly critical in times of volatile demand.
As a provider of innovative solutions, Complex Pharmaceuticals pays particular attention to meeting regulatory requirements in packaging and logistics.
In doing so, Complex Pharmaceuticals not only contributes to national supply security but also supports the European strategy to make the supply of pharmaceutical products in Europe more resilient.
Framework conditions and cooperation with stakeholders
Ensuring the supply of pharmaceutical products in Austria is not the responsibility of the industry alone. It requires close cooperation among all relevant stakeholders:
- Authorities such as the BASG (Federal Office for Safety in Health Care) and the AGES (Austrian Agency for Health and Food Safety) monitor the availability of pharmaceutical products in Austria and regularly publish shortage lists. Their role is to ensure transparency, assess the supply situation, and, in urgent cases, provide expert support to the responsible ministries for measures such as export restrictions or mandatory reserves.
- Industry associations such as Pharmig and FOPI represent research-based pharmaceutical companies and the pharmaceutical industry and advocate to strengthen Austria as a location and reduce regulatory barriers.
- Policies at EU and federal level establish the framework conditions to support investment in production, research, and logistics. Strategies such as the European pharmaceutical strategy or national funding programmes are crucial for closing supply gaps in the long term.
- Industry partners such as Complex Pharmaceuticals are responsible for putting these political and regulatory frameworks into practice – through investments in modern infrastructure, sustainable production methods, and flexible supply models.
Monitoring and controlling data and processes at every stage of the supply chain is essential to ensure quality, transparency, and compliance. Only when these stakeholders work hand in hand can Austria strengthen its position as a stable pharmaceutical hub while simultaneously contributing to Europe’s supply sovereignty.
Future outlook: Pharmaceutical product supply in Austria up to 2030
The coming years will be decisive in determining how resilient the supply of pharmaceutical product in Austria will be. Policymakers, industry and society have recognised that shortages should no longer be seen as exceptions but rather as structural challenges.
Companies such as Complex Pharmaceuticals are therefore investing in:
- modern, GMP-compliant production and packaging lines
- Sustainability & digitalisation, to make processes more transparent and efficient
- flexible capacities ranging from micro batches to millions of units
In doing so, Austria actively contributes to strengthening Europe’s supply sovereignty and ensures that patients have access to a safe, rapid and reliable supply of pharmaceutical products.
Conclusion
The question of a stable supply of pharmaceutical products in Austria is more than a political debate – it’s a matter of patient safety and Europe’s competitiveness.
Complex Pharmaceuticals positions itself as a partner for pharmaceutical companies, biotech firms and healthcare organisations that want to secure their supply chains and set new standards.
Securing supply and reducing dependencies – together with Complex Pharmaceuticals.
Let’s discuss your individual challenges in a non-binding conversation and explore ways to make your production and supply chains resilient in the long term.
Questions and answers
Pharmaceutical product supply in Austria
Büro
Complex Pharmaceuticals GmbH
Storchengasse 1
1150 Wien | Austria
Telefon
Bürozeiten
Mo bis Fr. 09:00 bis 18:00 Uhr
Tel: +43 1 208 01 34